The study was a retrospective, multicenter, Italian dynamic cohort study conducted on 2576 adult patients with moderate-to-severe atopic dermatitis treated with DUPIXENT were collected from 24 dermatological centers from June 2018 to July 2022. Data are from patients observed at 4 months (N=2364), 12 months (N=2066), 24 months (N=1291), 36 months (N=601), and 48 months (N=110).16
Limitations of analysis:
Limitations include the retrospective nature of the study and dynamic cohort design that hindered considerations regarding drug survival. Patients were also treated with other atopic dermatitis medications.16